Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN)	Rapcabtagene autoleucel (YTB323)	Ongoing	Rapcabtagene autoleucel (YTB323)	2	CYTB323J12201	King Faisal Specialist Hospital and Research Center (Riyadh)
Impact of an Oxygen-Loaded Sustained-Release Hyaluronic Acid Hydrogel on Periodontal Pocket Depth Reduction and Pain Control: A Split-Mouth Randomized Clinical Trial	PI Initiative	Ongoing	Hyaluronic acid and Oxygel gel	4	OHGel2025	Dental Hospital of King Khalid University (Abha)
An Observational Multi-center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobiliary Cancers	AstraZeneca	Ongoing	Durvalumab	4	D419CR00035	King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Marstacimab Prophylaxis in Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors	Pfizer / MCT	Ongoing	Marstacimab	3	B7841007	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 3, Randomized, Double-Blind,Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease	Merck sharp & Dohme	Ongoing	Tulisokibart	3	NCT0643080	King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Hospital NG (Riyadh), King Saud University Medical City (Riyadh), King Abdullah Medical City Specialist Hospital (Makkah)
Prospective multi-country, real-world, multi-arm study of treatment PErsistence with RISankizumab in Psoriatic Arthritis	AbbVie / Ray	Ongoing	Risankizumab (Skyrizi®)	4	P24-390	King Fahad Medical City (Riyadh)
An Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis with Moderate-to-Severe Pruritus	Vifor Pharma, Inc. / Balsam	Ongoing	Difelikefalin	2	KOR-PED-202	King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah)
A Phase 2 / Phase 3, Multicenter, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Adaptive Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease during Vaso-Occlusive Crisis	CSL Behring LLC	Ongoing	CSL889	3	CSL889_2001	King Faisal Specialist Hospital and Research Center (Riyadh), King Khalid University Hospital (Riyadh), Prince Mohammad Bin Naser Hospital (Jazan)
Fluid Management in Sickle Cell Disease Vaso-occlusive Crisis: Restrictive versus Liberal Strategies: A Randomized Controlled Trial (FLASC Trial)	PI initiative	Ongoing	Sodium Chloride / Lactated Ringers	4	FLASC01	King Fahad University Hospital (Al-Khobar)
A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study To Assess The Efficacy And Safety of Induction and Maintenance Therapy with Ro7790121 in Patients with Moderately to Severely Active Crohn's Disease	Roche / IQVIA	Ongoing	Ro7790121	3	GA45331	King Faisal Specialist Hospital and Research Center (Riyadh), King Saud Medical City (Riyadh)